Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Opens Books to Roche in Hopes of Fetching More Cash

NEW YORK (GenomeWeb News) — Ventana Medical Systems has offered Roche a glimpse into its financial health as it hopes to convince the Swiss drug and diagnostics giant to spend some more on it than the $3 billion dollars it continues to offer.
Tucson, Ariz.-based Ventana, which has snubbed Roche’s unsolicited bid to acquire it at least four times, said it hopes the due diligence and related talks will “allow Roche to recognize the significant additional value inherent in Ventana's business.”
The step will give Roche access to information about Ventana’s business prospects and the value of its companion diagnostics.
Roche has extended at least four times its original offer to buy the diagnostics company for $75 a share, or around $3 billion dollars. Ventana has insisted that the offer, made in June, is too small. Today, it said the due-diligence agreement will make it evident that the standing offer is “grossly inadequate.”
Ventana added that it makes no assurances that this agreement allowing due diligence will lead to a merger, and reiterated that its board believes the current offer price “does not appropriately compensate Ventana’s stockholders for the inherent value of the company or its synergistic value to Roche.”

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.